First published 10/1/2026, 6:30:15 AM · Last updated 10/1/2026, 6:30:15 AM

Frailty in early Alzheimer's disease: Complementary clinical value and prognostic significance in biomarker-defined mild cognitive impairment due to Alzheimer's disease

A SAGE-published journal article (2026-04-21) examines frailty's clinical value and prognostic significance in biomarker-defined mild cognitive impairment due to Alzheimer's disease. The supplied excerpt contains only publisher and content-type and no additional study details.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article purports to provide clinical and prognostic insights for mild cognitive impairment due to Alzheimer's disease.

Sources

Frailty in early Alzheimer's disease: Complementary clinical value and prognostic significance in biomarker-defined mild cognitive impairment due to Alzheimer's disease

Report an issue